BRPI0408529A - derivados 6-sulfonamida de quinolina e cromeno como antagonistas dos receptores de androgênios - Google Patents

derivados 6-sulfonamida de quinolina e cromeno como antagonistas dos receptores de androgênios

Info

Publication number
BRPI0408529A
BRPI0408529A BRPI0408529-9A BRPI0408529A BRPI0408529A BR PI0408529 A BRPI0408529 A BR PI0408529A BR PI0408529 A BRPI0408529 A BR PI0408529A BR PI0408529 A BRPI0408529 A BR PI0408529A
Authority
BR
Brazil
Prior art keywords
quinoline
chromene
receptor antagonists
androgen receptor
sulfonamide derivatives
Prior art date
Application number
BRPI0408529-9A
Other languages
English (en)
Inventor
Daniel Yunlong Du
Martin James Procter
Matthew Colin Thor Fyfe
Vilasben Kanji Shah
Geoffrey Martyn Williams
Karen Lesley Schofield
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BRPI0408529A publication Critical patent/BRPI0408529A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/40—Nitrogen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/14—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 6 and unsubstituted in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"DERIVADOS 6-SULFONAMIDA DE QUINOLINA E CROMENO COMO ANTAGONISTAS DOS RECEPTORES DE ANDROGêNIOS". A presente invenção refere-se a derivados de quinolina e cromeno 6-sulfonamida de fórmula (I) com as definições de M, R¬ 1¬, R¬ 2¬, A e B de acordo com a reivindicação 1 e a sua utilização como antagonistas dos receptores de androgênios.
BRPI0408529-9A 2003-03-20 2004-03-17 derivados 6-sulfonamida de quinolina e cromeno como antagonistas dos receptores de androgênios BRPI0408529A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45631603P 2003-03-20 2003-03-20
PCT/IB2004/000856 WO2004083204A1 (en) 2003-03-20 2004-03-17 6-sulfonamide quinoline and chromene derivative as androgen receptor antagonists

Publications (1)

Publication Number Publication Date
BRPI0408529A true BRPI0408529A (pt) 2006-03-07

Family

ID=33030093

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408529-9A BRPI0408529A (pt) 2003-03-20 2004-03-17 derivados 6-sulfonamida de quinolina e cromeno como antagonistas dos receptores de androgênios

Country Status (7)

Country Link
US (1) US7009052B2 (pt)
EP (1) EP1608643A1 (pt)
JP (1) JP2006520780A (pt)
BR (1) BRPI0408529A (pt)
CA (1) CA2517446A1 (pt)
MX (1) MXPA05009988A (pt)
WO (1) WO2004083204A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2874922A1 (fr) * 2004-07-30 2006-03-10 Palumed Sa Molecules hybrides qa ou q est une aminoquinoleine et a est un residu antibiotique, leur synthese et leurs utilisations en tant qu'agent antibacterien
EP1771456A2 (fr) * 2004-07-30 2007-04-11 Palumed SA Molecules hybrides qa ou q est une aminoquinoleine et a est un residu antibiotique, leur synthese et leurs utilisations en tant qu'agent antibacterien
KR20080021030A (ko) * 2005-05-16 2008-03-06 버텍스 파마슈티칼스 인코포레이티드 이온 채널 조절인자로서의 바이사이클릭 유도체
US8022138B2 (en) * 2006-05-18 2011-09-20 Dow Global Technologies Llc Polyurethane-urea polymers derived from cyclohexane dimethanol
EP2271685B1 (en) * 2007-12-26 2018-01-03 Dow Global Technologies LLC Polyurethane dispersions and coatings produced therefrom
US9776995B2 (en) * 2013-06-12 2017-10-03 Amgen Inc. Bicyclic sulfonamide compounds as sodium channel inhibitors
WO2015109056A1 (en) * 2014-01-17 2015-07-23 The Board Of Trustees Of The Leland Stanford Junior University 6,7-TRANS CEPHALOSPORIN-BASED PROBES FOR DETECTING BACTERIA EXPRESSING A METALLO-β-LACTAMASE
CA2959100A1 (en) * 2014-09-01 2016-03-10 Ucl Business Plc Quinolones as inhibitors of class iv bromodomain proteins
MA41140A (fr) 2014-12-12 2017-10-17 Cancer Research Tech Ltd Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg
MA41179A (fr) 2014-12-19 2017-10-24 Cancer Research Tech Ltd Composés inhibiteurs de parg
CN109730996B (zh) * 2017-03-01 2021-08-24 浙江大学 喹啉结构类型雄激素受体拮抗剂及其应用
JP7739051B2 (ja) 2020-06-10 2025-09-16 アムジエン・インコーポレーテツド シクロブチルジヒドロキノリンスルホンアミド化合物
WO2023067192A1 (en) * 2021-10-21 2023-04-27 Consejo Superior De Investigaciones Cientificas (Csic) Methods for improving abiotic stress resistance
AR128846A1 (es) 2022-03-23 2024-06-19 Ideaya Biosciences Inc Compuestos de indazol sustituidos con piperazina como inhibidores de parg
EP4559671A1 (en) 2023-11-27 2025-05-28 Henkel AG & Co. KGaA Method of separating bonded articles
EP4559672A1 (en) 2023-11-27 2025-05-28 Henkel AG & Co. KGaA Method of separating bonded articles

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023038A1 (en) 1992-05-20 1993-11-25 Merck & Co., Inc. 17-AMINO SUBSTITUTED 4-AZASTEROID 5α-REDUCTASE INHIBITORS
FR2706454B1 (fr) * 1993-06-17 1995-09-15 Roussel Uclaf Nouveaux 19-Nor stéroïdes, procédé et intermédiaires de préparation, application comme médicaments et compositions pharmaceutiques les contenant.
US6017924A (en) * 1996-06-27 2000-01-25 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
PL353792A1 (en) 1999-08-27 2003-12-01 Ligand Pharmaceuticals Incorporatedligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
US6667313B1 (en) 1999-08-27 2003-12-23 Ligand Pharmaceuticals Inc. 8-substituted-6-triflouromethyl-9-pyrido [3,2-G] quinoline compounds as androgen receptor modulators
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
GB0013060D0 (en) * 2000-05-31 2000-07-19 Astrazeneca Ab Chemical compounds
DE10034801A1 (de) * 2000-07-18 2002-01-31 Bayer Ag Substituierte Amidoalkyl-uracile und ihre Verwendung
EP1392434A4 (en) 2001-05-17 2008-07-02 Conocophillips Co PROCEDURE FOR REGENERATING A PRESSURE VARIATION CATALYST FOR A FISCHER-TROPSCH CATALYST

Also Published As

Publication number Publication date
MXPA05009988A (es) 2005-11-04
JP2006520780A (ja) 2006-09-14
WO2004083204A1 (en) 2004-09-30
US20050004367A1 (en) 2005-01-06
CA2517446A1 (en) 2004-09-30
US7009052B2 (en) 2006-03-07
EP1608643A1 (en) 2005-12-28

Similar Documents

Publication Publication Date Title
BR0115436A (pt) Compostos de piperazinilpirazina atuando como antagonistas do receptor 5ht-2 de serotonina
CR10303A (es) "derivados de quinolina y su uso com pesticidas"
BRPI0507574A (pt) piridazinonas como antagonistas de alfa 4 integrinas
BRPI0507462A (pt) compostos de quinolina substituìdos
BRPI0409164A (pt) pirazóis substituìdos
ATE344261T1 (de) Cyclische n-aroylamine als orexinrezeptorantagonisten
ECSP066773A (es) Intermediarios de quinolina como inhibidores de receptores de tirosina quinasas y la síntesis de los mismos
WO2008038251A3 (en) 3-aza-bicyclo[3.1.0]hexane derivatives
ATE349434T1 (de) Lactamderivaten zur verwendung als humane 11cby rezeptorantagonisten
ATE484505T1 (de) 5-sulfanylmethylä1,2,4ütriazolä1,5-aüpyrimidin- - olderivate als cxcr2-antagonisten
EA200300829A1 (ru) Производные 1-арил- или 1-алкилсульфонилбензазола в качестве лигандов 5-гидрокситриптамина-6
DE60228487D1 (de) Ethylenediaminderivate und ihre verwendung als orexinrezeptorantagonisten
BRPI0414592A (pt) antagonistas de receptores de trombina
EA200700047A1 (ru) Новые алкильные производные в качестве метаботропных рецепторов глутамата
DE60320529D1 (de) Chinolinderivate als npy antagonisten
PA8774201A1 (es) Antagonista del receptor
BRPI0414598A (pt) indóis substituìdos
BR0213464A (pt) Derivados de 3-azabiciclo[3.1.0]hexano como antagonistas receptores de opióide
DE602007004999D1 (de) 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen-derivate als orexinrezeptor-antagonisten
UY30534A1 (es) Derivados de 5,6-bisaril-2-piridin-carboxamida, su preparacion y su aplicacion en terapéutica como antagonistas de los receptores de urotensina ii
BR0206595A (pt) Composto, composição farmacêutica, e uso de um composto
MXPA05009988A (es) Derivados de 6-sulfonamida quinolina y cromeno como antagonistas de los receptores de androgenos.
HN2001000280A (es) Derivados de piperidina como antagonstas selectivos de subtipo de n - metil - d - aspartato.
ATE421511T1 (de) Indol-3-carbonyl-spiro-piperidinderivate als antagonisten des v1a-rezeptors
BRPI0506477A (pt) compostos farmaceuticamente úteis e inovadores

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.